Melane Sampson, Author at BioTuesdays

Developments

Immutep reports positive Phase 1 results for IMP761 in autoimmune diseases

Immutep (ASX: IMM; NASDAQ: IMMP) has announced positive Phase 1 results for IMP761, a first-in-class LAG-3 agonist antibody designed to potentially supress pathogenic T cell responses in autoimmune diseases. According...

March 19, 2026

Executive Moves

Evolent names Archie Mayani as CPO

Evolent Health (NYSE: EVH) has announced the appointment of healthcare technology leader and AI innovator, Archie Mayani, as chief product officer (CPO). Ms. Mayani brings more than two decades of leadership experience...

March 19, 2026

Developments

Niagen increases share repurchase program to $20 million

Niagen Bioscience (NASDAQ: NAGE) has announced that its board of directors has authorized an increase to the company’s previously disclosed share repurchase program, raising the total authorization from $10 million to...

March 19, 2026

Developments

Picard / SynCardia’s Total Artificial Heart enables four-year bridge to transplant

Picard Medical (NYSE American: PMI) has announced that a 29-year-old patient successfully received a donor heart transplant after more than four years of being fully supported by the SynCardia Total Artificial...

March 17, 2026

Feature

PolarityBio changing the trajectory of wound care with autologous regenerative biologics

Closely held PolarityBio is developing investigational regenerative biologics for chronic wound healing, targeting some of the most refractory wounds in medicine. The company’s lead program and first entry into the...

March 17, 2026

Developments

Trial finds Profound’s TULSA Procedure significantly improves erectile function and continence vs. robotic radical prostatectomy

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic...

March 16, 2026

Developments

Firefly announces discovery of new brain wave biomarkers for differential diagnosis of ADHD

Firefly Neuroscience (NASDAQ: AIFF) has announced advancements in research using resting EEG/cognitive EEG (ERP) brain scans, collected on its FDA 510(k)-cleared Evoke System, to potentially distinguish among the three...

March 13, 2026

Executive Moves

MindMaze appoints Zach Henderson as CEO

MindMaze Therapeutics (SIX: MMTX) has announced the appointment of health tech veteran Zach Henderson as chief executive officer (CEO). With more than 30 years of experience scaling healthcare technology platforms and...

March 12, 2026

Developments

REGENXBIO reports positive data from Phase 1/2 trial of RGX-202 in DMD

REGENXBIO (NASDAQ: RGNX) has announced new positive interim data from the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202—a potential best-in-class therapy for Duchenne muscular dystrophy (DMD). Trial investigator Carolina...

March 11, 2026

Developments

Clearmind advances recruitment for third cohort of CMND-100 trial at leading sites

Clearmind Medicine (NASDAQ: CMND) has announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase 1/2a trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI...

March 11, 2026

Author - Melane Sampson

Immutep reports positive Phase 1 results for IMP761 in autoimmune diseases

Evolent names Archie Mayani as CPO

Niagen increases share repurchase program to $20 million

Picard / SynCardia’s Total Artificial Heart enables four-year bridge to transplant

PolarityBio changing the trajectory of wound care with autologous regenerative biologics

Trial finds Profound’s TULSA Procedure significantly improves erectile function and continence vs. robotic radical prostatectomy

Firefly announces discovery of new brain wave biomarkers for differential diagnosis of ADHD

MindMaze appoints Zach Henderson as CEO

REGENXBIO reports positive data from Phase 1/2 trial of RGX-202 in DMD

Clearmind advances recruitment for third cohort of CMND-100 trial at leading sites

Subscribe